Topics
Gliomas | Treatment | Targeted therapy | Vorasidenib
Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > Vorasidenib
Lin MD, Tsai AC, Abdullah KG, McBrayer SK, Shi DD.
Treatment
of IDH-mutant glioma in the INDIGO era.
NPJ
Precis Oncol. 2024 Jul 19;8(1):149. doi:
10.1038/s41698-024-00646-2. PMID:
39025958. Review. ˍ
Mullard A.
FDA approves IDH1 and IDH2
inhibitor for brain cancer.
Nat Rev Drug Discov. 2024
Aug 16. doi:
10.1038/d41573-024-00135-y. PMID:
39152244. News˰ ˍ
Nakhate V, Lasica AB, Wen PY.
The Role
of Mutant IDH Inhibitors in the Treatment of Glioma.
Curr
Neurol Neurosci Rep. 2024 Sep 20. doi:
10.1007/s11910-024-01378-3. PMID:
39302605. Review˰ ˍ
Darlix A, Preusser M, Hervey-Jumper SL, Shih HA, Mandonnet E,
Taylor JW.
Who will benefit from
vorasidenib? Review of data from the literature and open
questions.
Neurooncol
Pract. 2024 Nov 14;12(Suppl 1):i6-i18. doi:
10.1093/nop/npae104. PMID:
39776530. Review. ˍ
Patel MP, Serventi JN, Dunbar EM, Oliver K, Piil K, Seute T, Chang
S.
Vorasidenib: Patient and caregiver
information sheet.
Neurooncol
Pract. 2024 Nov 25;12(Suppl 1):i26-i28. doi:
10.1093/nop/npae081. PMID:
39776531. Review. ˍ
Still MEH, Moor RSF, Ghiaseddin AP, Leibetseder A, Hottinger AF,
Berghoff A, Leung D.
How do I
prescribe and manage mIDH inhibitors in patients with IDH-mutant
glioma?
Neurooncol
Pract. 2024 Dec 3;12(Suppl 1):i19-i25. doi:
10.1093/nop/npae112. PMID:
39776526. Review. ˍ
Roth P, Capper D, Calabrese E, Halasz LM, Jakola AS.
Role
of the tumor board when prescribing mutant isocitrate
dehydrogenase inhibitors to patients with isocitrate
dehydrogenase-mutant glioma.
Neurooncol
Pract. 2024 Dec 4;12(Suppl 1):i29-i37. doi:
10.1093/nop/npae100. PMID:
39776528. Review. ˍ
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB,
Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz
LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M,
Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G,
Rahman R, Hervey-Jumper S, Chang SM, Wen PY.
The
role of vorasidenib in the treatment of isocitrate
dehydrogenase-mutant glioma.
Neuro
Oncol. 2024 Dec 25:noae259. doi:
10.1093/neuonc/noae259. PMID:
39723472. Review: Interventional study. ˍ